$242.84
-1.28(-0.53%)
Mkt Cap $585.2B
$146.36
$248.56
52-Week Range
At A Glance
1
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Heal...
2
Revenue is primarily driven by DARZALEX (13.3%) and Stelara (10.2%).
3
Most recently: Results of operations and financial condition On January 21, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing (2026-01-21).
$585.2B
Market Cap
$93.5B
Revenue
$26.6B
Net Income
Employees138,100
Fundamentals
How The Business Makes Money
Revenue by Segment
DARZALEX13.3%($71.5B)
Stelara10.2%($54.6B)
GENERAL6.1%($32.6B)
ELECTROPHYSIOLOGY5.8%($31.2B)
ADVANCED5.1%($27.5B)
INVEGASUSTENNAXEPLIONTRINZATREVICTA4.5%($24.3B)
Tremfya4.5%($23.9B)
CONTACTLENSESOTHER4.2%($22.7B)
TRAUMA3.4%($18.3B)
IMBRUVICA3.4%($18.3B)
Erleada3.3%($17.9B)
SPINESPORTSOTHER3.3%($17.4B)
Xarelto2.7%($14.7B)
Simponi Simponi Aria2.6%($14.1B)
OPSUMIT2.4%($13.0B)
UPTRAVI2%($10.6B)
Remicade1.9%($10.4B)
PREZISTAPREZCOBIXREZOLSTASYMTUZA1.9%($10.3B)
HIPS1.8%($9.7B)
KNEES1.7%($9.2B)
Abiomed1.7%($9.1B)
SURGICAL1.6%($8.7B)
EDURAN Trilpivirine1.5%($7.8B)
OTHERNEUROSCIENCE1.4%($7.6B)
Other1.4%($7.3B)
SPRAVATO1.3%($6.9B)
CARVYKTI1.2%($6.7B)
ZYTIGA0.8%($4.0B)
CONCERTA Methylphenidate0.7%($4.0B)
Other Infectious Diseases0.7%($4.0B)
Shockwave Medical Inc.0.6%($3.4B)
TECVAYLI0.6%($3.2B)
RYBREVANTLAZCLUZE0.4%($2.3B)
Other Cardiovascular0.4%($2.3B)
Other Oncology0.4%($2.0B)
TALVEY0.3%($1.6B)
Other Pulmonary Hypertension0.3%($1.4B)
CAPLYTA0.3%($1.4B)
Other Immunology0%($150M)
Revenue by Geography
US56.1%($752.2B)
Non Us35.1%($470.7B)
Europe4.6%($62.2B)
Asia Pacific Africa3.1%($41.4B)
Western Hemisphere Excluding US1.1%($14.1B)
UNITEDSTATES Exports0%($319M)
Activity
Analyst View
Company Profile
CIK0000200406
ISINUS4781601046
CUSIP478160104
Phone732 524 0400
AddressOne Johnson & Johnson Plaza, New Brunswick, NJ, 08933, US
SEC EDGAR